FindTrial
Sign In

Pioglitazone study in Blood cancer

Early introduction of Pioglitazone to Imatinib to enhance outcome in chronic myeloid leukaemia in chronic phase - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017394
Enrollment
82
Registered
2019-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive

Interventions

Intervention1: Pioglitazone tablets: Intervention is Tab.Pioglitazone and the comparator agent is Placebo. Both arms will receive Tab.Imatinib at 400 mg od, the standard of care. Pioglitazone will be

Sponsors

Christian Medical College Vellore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed CML in CP (chronic phase), No comorbidities, Age >18 years, < 60 years

Exclusion criteria

Exclusion criteria: Diabetes mellitus, previous history of allergy or intolerance to Pioglitazone, CCF.

Design outcomes

Primary

MeasureTime frame
Proportion of patients achieving Major Molecular Response (MMR) at 12 monthsTimepoint: Proportion of patients achieving Major Molecular Response (MMR) at 12 months—

Secondary

MeasureTime frame
Proportion of patients achieving Major Reponse (MR) 4.5 or better response at 12 monthsTimepoint: At 12 months—

Countries

India

Contacts

Public ContactAby Abraham

Christian Medical College, Vellore

aby@cmcvellore.ac.in04162282352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026